concentrations ≤20 ng/mL were randomly assigned to receive a supervised monthly oral vitamin D 3 of 18,000 IU (~600 IU/day, n = 17), 60,000 IU (~2000 IU/day, n = 18), 120,000 IU (~4000 IU/day, n = 18), or placebo (n = 17).
Background
African Americans as compared to their Caucasian peers have disproportionately high prevalence of suboptimal vitamin D status [1] [2] [3] . Obesity, a risk factor for poor vitamin D status, also negatively impacts 25(OH)D responses to vitamin D supplementation [3] [4] [5] . The most recent Institute of Medicine (IOM) Report identified an urgent need to conduct randomized clinical trials (RCTs) of vitamin D supplementation to clarify dose-response to intake, with a special emphasis on the individuals with excess adiposity and dark skin pigmentations [6] . Given the lack of conclusive evidence, the IOM bases its Recommended Dietary Allowance (RDA) for vitamin D on bone health, which is 600-800 IU/day corresponding to a 25(OH)D serum level of~20 ng/mL [6] . The target 25(OH)D level is~30 ng/mL recommended by many other experts for large swaths of the population, although it is controversial [7] [8] [9] [10] .
In an earlier placebo-controlled RCT, 208 healthy postmenopausal African American females residing in New York (~40.8°N latitude) were given a daily dose of 800 IU vitamin D plus calcium for two years [11] . The mean 25(OH)D levels remained <30 ng/mL at the end of the second year, but reached up to 35 ng/mL within three months after the dose was increased to 2000 IU. However, approximately 40 % of participants still had 25(OH)D levels between 20-30 ng/mL. The authors suggested a dose between 2800-4000 IU/day to optimize vitamin D levels in African Americans, according to the vitamin D algorithm. Gallagher and colleagues [12] supplemented 110 postmenopausal African American females with suboptimal vitamin D status living in Nebraska (~41°N latitude) and Indiana (~40°N latitude) with daily doses between 400-4800 IU vitamin D plus calcium for 12 months. The authors determined that a daily dose of 1600 IU was required to achieve the level of 25(OH)D ≥30 ng/mL. In another study of younger (25-45 years) African American (n = 39) and Caucasian (n = 90) females living in Nebraska, 400-2400 IU/day vitamin D plus calcium supplements resulted in a dose and time-responsive increase in serum 25(OH)D concentrations. The authors estimated a daily dose between 800-1600 IU in young African American females, to achieve a level of serum 25(OH)D at 20 ng/mL [12] . More recently, Ng et al., [13] supplemented 30-80 years-old 328 African Americans living in Boston (42°N latitude) with daily 1000, 2000, or 4000 IU of vitamin D plus calcium for 3 months. It was estimated that a dose of 1640 IU and 4000 IU vitamin D is desired to achieve the 25(OH)D concentrations of ≥20 ng/mL and ≥33 ng/mL, respectively. However, dose-responsive RCTs with exclusive vitamin D supplementation are lacking in young African Americans, particularly in overweight/ obese individuals. 
Subject and methods

Participants
In this randomized, double-blinded, placebo-controlled clinical trial (clinicaltrials.gov registration#: NCT01583621), participants were recruited from community by advertisements and by word of mouth. Inclusion criteria were selfreported African American race, age between 13-45 years, overweight/obese, no pregnancy, no lactation, no known acute or chronic illnesses, no use of any prescription medications, birth control pills, herbal, multi-vitamin or mineral supplementations, and suboptimal vitamin D status (serum 25(OH)D concentrations of ≤20 ng/mL) [6] at screening visit. Overweight/obesity was defined by body mass index (BMI) ≥25 kg/m 2 for adults and ≥85 th percentile for age and sex for adolescents according to the Center of Disease Control and Prevention (CDC) criteria. The study was approved by the institutional review board (IRB) at the Georgia Regents University (GRU). Adolescents and their guardians provided informed written assent and consent, respectively; and the adults provided informed consent. A total of 129 overweight/obese African Americans living in Augusta, GA and surrounding areas were screened and 70 eligible subjects were enrolled and followed-up in the between December, 2011 and November, 2012. The trial registration on clinicaltrials.gov was delayed due to an oversight, and the authors confirm that all ongoing and related trials for this intervention are registered.
Randomization and vitamin D 3 dosing
As presented in Fig. 1 , participants were randomly assigned to either of the following vitamin D supplement groups: 18,000 IU (equivalent to 600 IU/day), 60,000 IU (equivalent to 2000 IU/day), 120,000 IU (equivalent to 4000 IU/day) or a placebo for 16 weeks by supervised monthly dosing. The vitamin D and placebo capsules were provided by the Bio-Tech Pharmacal, Fayetteville, AR, and the GRU clinical research pharmacy generated the randomization codes and dispensed the study capsules. The GRU clinical pharmacy maintained the randomization codes until the end of the study and did not have any direct role in the data collection.
Laboratory tests
Fasting blood samples and spot urine samples were obtained at baseline, 8-and 16-weeks, which were frozen and stored at −80°C until assayed. Serum 25(OH)D concentrations were measured using enzyme immunoassay (Immunodiagnostic Systems, Fountain Hills, AZ). The intra-and inter-assay coefficients of variation (CV) were 5.6 and 6.6 %, respectively. Our laboratory is certified by the vitamin D external quality assessment scheme (DEQAS), an international program monitoring accuracy of 25(OH)D measurements. Plasma 1,25(OH) 2 D levels were measured using radioimmunoassay [24] . The intraand inter-assay CVs were 9.8 % and 12.6 %, respectively. Plasma bioactive intact parathyroid hormone (iPTH) concentrations were measured using an enzyme-linked immunosorbent assay (ELISA, Immutopics, San Clemente, CA). Plasma intact FGF-23 concentrations were measured using ELISA (Immunotopics, Inc., San Clemente, CA). The intra-and inter-assay CVs were and 6.7 % and 9.8 %, respectively. Plasma phosphorus was determined using colorimetric assays kits (Point Scientific, Inc., Canton, MI). The intra-and inter-assay CVs were 6.4 % and 8.1 %, respectively. Spot urine calcium levels were measured by 
Sample size estimation
Power calculations were computed based on primary outcomes 25(OH)D, 1,25(OH) 2 D, iPTH, and FGF-23. The computations are based upon the linear contrast approach for the main effect of treatment, rather than the traditional omnibus F-test followed by post hoc pairwise comparisons, because a pre-specified contrast conditioned on the ordering of responses is more powerful to detect the expected pattern, without sacrificing control of type I error. Required are assumptions concerning the difference in mean 16-week changes in the response (i.e., differences in the mean gain scores) across treatment arms, and the variance of the gain score, from which effect size is computed. Using previous data, including ours, [3, 25, 26] IU groups would have one-quarter and onehalf the mean change, respectively, of that occurring in the 4000 IU group, relative to the mean change in the control group. We determined that 10-16 subjects/group would provide 81-96 % power (α = 0.05) to detect a difference in mean change of the outcome variable between groups. With a given sample size of 16 subject/group (α-level set at 0.05), the proposed study will have power of 0.81. Assuming a 10 % sample size loss due to attrition or insufficient quality of measurements, a starting sample size of 18 subjects per group will preserve power of the study design.
Statistical analyses
All statistical analyses were performed using SPSS software (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, version 21.0. Armonk, NY) and statistical significance was set at P < 0.05. Analysis of variance was used to compare group differences at baseline for normally distributed variables or by Kruskal-Wallis test, otherwise. Differences in proportions were tested by chisquare test of goodness of fit.
Repeated-measures mixed-models were used with maximum likelihood estimation in an intention-to-treat analysis of each outcome measure using all available data. Base models for each outcome measure included the fixed effects of intervention group (placebo, 600 IU/day, 2000 IU/day, or 4000 IU/day) and measurement time (baseline, 8-weeks, or 16-weeks) and their interaction.
The modeled covariance structure between measurement periods was unstructured, which used all available measurements on the same subject, including those from subjects who dropped out of the study. Because significant group differences in baseline characteristics were not detected, covariates were not considered in the primary analyses. However, secondary analyses were performed to consider potential effects of age, gender, season, and BMI. The linear contrasts across the four groups of the change over time tested the dose-response effects of vitamin D supplementation, and the pairwise comparisons of changes in the outcome variables between groups were performed. Table 1 displays the baseline characteristics of the participants. Of 129 screened,~75 % (96 individuals) met the inclusion criteria. A total of 70 subjects were available at baseline. The baseline serum 25(OH)D in the entire sample was 14.77 ± 0.6 ng/mL. Age, gender distribution, BMI, serum 25(OH)D, plasma iPTH, 1,25(OH) 2 D, FGF-23 and phosphorus did not differ among the groups at baseline. No side effects were observed during the study period. A total of 5 participants discontinued the study either due to loss of follow up (2 subjects), positive pregnancy test (2 subjects) or diagnosis of diabetes (1 subject).
Results
Baseline clinical characteristics
(OH)D: dose and time responses at 8-and 16-weeks
There were overall group by time interactions (P < 0.01), suggesting dose-and time-dependent increases in serum 25(OH)D concentrations to the monthly vitamin D supplements (Fig. 2) . In the 600 IU group, mean 25(OH)D concentrations remained~20 ng/mL both at 8-(21.0 ± 1.0 ng/mL) and 16-weeks (22.61 ± 1.24 ng/mL). On the other hand, both 2000 IU and 4000 IU vitamin D groups raised mean 25(OH)D concentrations to the level of 30 ng/mL at 8-weeks (30.50 ± 2.1 and 35.66 ± 3.4 ng/mL, respectively), and maintained at a similar level (36.01 ± 3.1 and 34.80 ± 2.4 ng/mL, respectively) at 16-weeks.
In post-hoc group-wise comparison, the changes in 25(OH)D concentrations from baseline to 8-weeks in the 4000 IU group (22.41 ± 1.8 ng/mL) were significantly greater compared to the 2000 IU (14.56 ± 1.8 ng/ mL, p < 0.01), 600 IU (7.06 ± 2.0 ng/mL, p < 0.01) and placebo (0.12 ± 1.9 ng/mL, p < 0.01) groups. (Fig. 3) . In post-hoc group-wise comparisons, the changes from baseline to 8-weeks, but not the changes from baseline to 16-weeks, were significantly higher both in the 4000 IU and 2000 IU groups versus the placebo group. However, only the 4000 IU group showed a greater increase than the 600 IU group (8.89 ± 2.0 pg/mL vs. [28] .
One of the most interesting findings of our study was that the 25 [32] . The disparities of the findings could be due to the differences in the baseline 25(OH)D levels or the frequency of dosing.
iPTH
We observed dose-and time-responsive reductions in plasma iPTH concentrations, whereas mixed results in this regard have been reported in the literature [12, 29, 32] . The present study demonstrated that 4000 IU, rather than 600 or 2000 IU by monthly dosing, significantly reduced iPTH at 8-and 16-weeks. Our group previously reported that iPTH concentrations in response to 2000 IU/day was unchanged in African American adolescents [3] and adults [26] , which is in agreement with the findings of others [33] . These findings may reinforce it that a dose higher than 2000 IU/day would be required to suppress iPTH. However, a higher daily vitamin D dose, i.e.,~5000 IU/day, modestly yet insignificantly reduced iPTH, as compared to 1000 and 2000 IU/day, respectively [33, 34] . Thus, our results might indicate the superiority of monthly dosing in suppressing iPTH.
FGF-23 and phosphorus
To the best of our knowledge, our study is among the few to report FGF-23 and phosphorus in apparently healthy African Americans, and the first to study the dose-responsiveness to vitamin D supplementation. Of note, baseline plasma intact FGF-23 levels in our African American subjects were lower than previously reported [35, 36] . We did not observe any dose-or timedependent changes in either FGF-23 or phosphorus. 
Strengths and limitations
There are several strengths in the present study. We exclusively recruited overweight/obese African American participants with suboptimal vitamin D status. We comprehensively analyzed various vitamin D related biomarkers, and administered vitamin D supplements without calcium supplements. The doses selected in this study were based on the current RDA and UL by the IOM, [6] and monthly supervised dosing scheme was undertaken to ensure 100 % compliance. Although monthly vitamin D dosing has been previously administered, our study is the first to use a dose-response design. The limitations of our study are worth mentioning. First, the bioavailability of 25(OH)D was not included in the current study, although we only supplemented African Americans [40] . Second, the participants were recruited in different seasons. However, only individuals with suboptimal vitamin D status were recruited irrespective of the season of enrollment, and the results did not alter after adjusting for seasons. Third, the female representation was higher in our sample compared to males. However, the gender distribution was not different among groups, and the results did not differ after adjusting for gender as a potential confounder. Fourth, the objective of the current study is to study a panel of circulating vitamin D biomarkers in response to vitamin D supplementation. Skeletal and extra-skeletal functional outcomes, that are not part of this study, would deserve investigations in the future, to help to select doses and time scheme. Finally, the sample size in each group was relatively small, which emphasizes the need for larger studies.
Conclusions
In 
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